Literature DB >> 7620543

Gastroesophageal reflux laryngitis resistant to omeprazole therapy.

I D Bough1, R T Sataloff, D O Castell, J R Hills, R M Gideon, J R Spiegel.   

Abstract

Gastroesophageal reflux disease (GERD) is known to cause a variety of symptoms that lead a patient to seek otolaryngologic care. New advances in the treatment of GERD have enabled otolaryngologists to eliminate most of the signs and symptoms caused by acid reflux. Omeprazole, the most recent pharmacologic advancement, has been reported to be universally successful in controlling acid release from the stomach of patients with GERD. This report describes a series of patients with GERD for whom high-dose omeprazole therapy was not successful in completely reducing gastric acid levels of GERD symptomatology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620543     DOI: 10.1016/s0892-1997(05)80254-1

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  5 in total

Review 1.  The laryngeal and esophageal manifestations of Sjögren's syndrome.

Authors:  Peter C Belafsky; Gregory N Postma
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

2.  Optimal treatment of laryngopharyngeal reflux disease.

Authors:  Irene Martinucci; Nicola de Bortoli; Edoardo Savarino; Andrea Nacci; Salvatore Osvaldo Romeo; Massimo Bellini; Vincenzo Savarino; Bruno Fattori; Santino Marchi
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

Review 3.  Extraoesophageal manifestations of gastro-oesophageal reflux.

Authors:  J Poelmans; J Tack
Journal:  Gut       Date:  2005-10       Impact factor: 23.059

4.  Laryngopharyngeal reflux disease with nocturnal gastric acid breakthrough while on proton pump inhibitor therapy.

Authors:  Kiminori Sato
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-07-15       Impact factor: 2.503

Review 5.  Atypical manifestations of gastro-oesophageal reflux.

Authors:  W J Issing; P D Karkos
Journal:  J R Soc Med       Date:  2003-10       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.